Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy

Journal of Physiology

Volumn 592, Issue 21, 2014, Pages 4627-4638

  Tidball, James G ^a,b   Wehling Henricks, Michelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MICRORNA; NEURONAL NITRIC OXIDE SYNTHASE; SCATTER FACTOR; NITRIC OXIDE;

CELL ACTIVATION; CYTOSOL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEFICIENCY; ENZYME LOCALIZATION; ENZYME RELEASE; ENZYME SYNTHESIS; GLYCOGEN METABOLISM; HISTONE ACETYLATION; HUMAN; IMMUNOHISTOCHEMISTRY; MUSCULAR DYSTROPHY; MYOFIBROSIS; MYOSITIS; NEGATIVE FEEDBACK; NEURONAL NITRIC OXIDE SYNTHASE DEFICIENCY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REVIEW; SARCOLEMMA; SATELLITE CELL; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; DEFICIENCY; DUCHENNE MUSCULAR DYSTROPHY; ENZYMOLOGY; GENETICS; METABOLISM;

ANIMALS; DYSTROPHIN; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; SARCOLEMMA;

EID: 84928411365     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.274878     Document Type: Review

References (69)

1. Abu-Soud HM & Hazen SL (2000). Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem 275, 5425-5430.
2. Allen RE, Sheehan SM, Taylor RG, Kendall TL & Rice GM (1995). Hepatocyte growth factor activates quiescent skeletal muscle satellite cells in vitro. J Cell Physiol 165, 307-312.
3. Anderson JE (2000). A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell 11, 1859-1874.
4. Arning L, Jagiello P, Schara U, Vorgerd M, Dahmen N, Gencikova A, Mortier W, Epplen JT & Gencik M (2004). Transcriptional profiles from patients with dystrophinopathies and limb girdle muscular dystrophies as determined by qRT-PCR. J Neurol 251, 72-78.
5. Barton ER, Morris L, Kawana M, Bish LT & Toursel T (2005). Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve 32, 751-760.
6. Brenman JE, Chao DS, Xia H, Aldape K & Bredt DS (1995). Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82, 743-752.
7. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, Perrotta C, Monopoli A, Sanvito F, Bottinelli R, Ongini E, Cossu G & Clementi E (2007). Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A 104, 264-269.
8. Buono R, Vantaggiato C, Pisa V, Azzoni E, Bassi MT, Brunelli S, Sciorati C & Clementi E (2012). Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP. Stem Cells 30,197-209.
9. Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M, Nicoletti C, Santini T, Sthandier O, Barberi L, Auricchio A, Musaro A & Bozzoni I (2010). MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab 12, 341-351.
10. ChangWJ, Iannaccone ST, Lau KS, Masters BS, McCabe TJ, McMillan K, Padre RC, Spencer MJ, Tidball JG & Stull JT (1996). Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U S A 93, 9142-9147.
11. Clancy RM, Leszczynska-Piziak J & Abramson SB (1992). Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 9, 1116-1121.
12. ColeMA, Rafael JA, TaylorDJ, Lodi R, Davies KE & Styles P (2002). A quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin. Neuromuscul Disord 12, 247-257.
13. Colussi C,Mozzetta C,Gurtner A, Illi B, Rosati J, Straino S, Ragone G, Pescatori M, Zaccagnini G, Antonini A, Minetti G, Martelli F, Piaggio G, Gallinari P, Steinkuhler C, Clementi E, Dell'Aversana C, Altucci L, Mai A, Capogrossi MC, Puri PL & Gaetano C (2008). HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A 105, 19183-19187.
14. Colussi C,Gurtner A, Rosati J, Illi B, Ragone G, PiaggioG, Moggio M, Lamperti C, D'Angelo G, Clementi E, Minetti G, Mozzetta C, Antonini A, Capogrossi MC, Puri PL & Gaetano C (2009). Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy. FASEB J 23, 2131-2141.
15. Cordani N, Pisa V, Pozzi L, Sciorati C & Clementi E (2014). Nitric oxide controls fat deposition in dystrophic skeletal muscle by regulating fibro-adipogenic precursor differentiation. Stem Cells 32, 874-885.
16. Cornelison DD & Wold BJ (1997). Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev Biol 191, 270-283.
17. Crosbie RH, Straub V, Yun HY, Lee JC, Rafael JA, Chamberlain JS, Dawson VL, Dawson TM & Campbell KP (1998). mdx muscle pathology is independent of nNOS perturbation. Hum Mol Genet 7, 823-829.
18. Finsterer J & Stollberger C (2003). The heart in human dystrophinopathies. Cardiology 99, 1-19.
19. Frascarelli M, Rocchi L & Feola I (1988). EMG computerized analysis of localized fatigue in Duchenne muscular dystrophy. Muscle Nerve 11, 757-761.
20. Gentil C, Leturcq F, Ben Yaou R, Kaplan JC, Laforet P, Penisson-Besnier I, Espil-Taris C, Voit T, Garcia L & Pietri-Rouxel F (2012). Variable phenotype of del45-55 Becker patients correlated with nNOSμ mislocalization and RYR1 hypernitrosylation. Hum Mol Genet 21, 3449-3460.
21. Gladwin MT, Crawford JH & Patel RP (2004). The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med 36, 707-717.
22. Gucuyener K, Ergenekon E, Erbas D, Pinarli G & Serdaroglu A (2000). The serum nitric oxide levels in patients with Duchenne muscular dystrophy. Brain Dev 22, 181-183.
23. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV & Chamberlain JS (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8, 253-261.
24. Haslett JN, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, Kohane IS, Beggs AH & Kunkel LM (2002). Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A 99, 15000-15005.
25. Huang Y, Majumdar S, Genant HK, Chan WP, Sharma KR, Yu P, Mynhier M & Miller RG (1994). Quantitative MR relaxometry study of muscle composition and function in Duchenne muscular dystrophy. J Magn Reson Imaging 4, 59-64.
26. Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E, Minetti G, Zhao P, Hoffman EP, Puri PL & Sartorelli V (2004). Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 6, 673-684.
27. Ignarro LJ (1989). Endothelium-derived nitric oxide: actions and properties. FASEB J 3, 31-36.
28. Ito N, Ruegg UT, Kudo A, Miyagoe-Suzuki Y & Takeda S (2013). Activation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. Nat Med 19, 101-106.
29. Judge LM, Haraguchi M & Chamberlain JS (2006). Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. J Cell Sci 119, 1537-1546.
30. Kameya S, Miyagoe Y, Nonaka I, Ikemoto T, Hanaoka K, Nabeshima Y & Takeda S (1999). a1-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J Biol Chem 274, 2193-2200.
31. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, Parikh SV,Weiss RM, Chamberlain JS, Moore SA & Campbell KP (2008). Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456, 511-515.
32. Lai Y, ThomasGD, Yue Y, YangHT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL & Duan D (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 119, 624-635.
33. Lee KH, Baek MY, Moon KY, Song WK, Chung CH, Ha DB & Kang MS (1994). Nitric oxide as a messenger molecule in myoblast fusion. J Biol Chem 269,14371-14374.
34. Li D, Yue Y, Lai Y, Hakim CH & Duan D (2011). Nitrosative stress elicited by nNOSμ delocalization inhibits muscle force in dystrophin-null mice. J Pathol 223, 88-98.
35. Liu P, Xu B, Hock CE, Nagele R, Sun FF & Wong PY (1998). NO modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R. Am J Physiol Heart Circ Physiol 275, H2191-H2198.
36. Lodi R, Kemp GJ, Muntoni F, Thompson CH, Rae C, Taylor J, Styles P & Taylor DJ (1999). Reduced cytosolic acidification during exercise suggests defective glycolytic activity in skeletal muscle of patients with Becker muscular dystrophy. An in vivo 31P magnetic resonance spectroscopy study. Brain 122, 121-130.
37. Martin EA, Barresi R, Byrne BJ, Tsimerinov EI, Scott BL, Walker AE, Gurudevan SV, Anene F, Elashoff RM, Thomas GD & Victor RG (2012). Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 4, 162ra155.
38. Miles AM, Bohle DS, Glassbrenner PA, Hansert B,Wink DA & Grisham MB (1996). Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J Biol Chem 271, 40-47.
39. Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, Fortuni S, Straino S, Sampaolesi M, Di Padova M, Illi B, Gallinari P, Steinkuhler C, Capogrossi MC, Sartorelli V, Bottinelli R, Gaetano C & Puri PL (2006). Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 12, 1147-1150.
40. Mizunoya W, Upadhaya R, Burczynski FJ,Wang G & Anderson JE (2011). Nitric oxide donors improve prednisone effects on muscular dystrophy in the mdx mouse diaphragm. Am J Physiol Cell Physiol 300, C1065-C1077.
41. Percival JM, Anderson KN, Gregorevic P, Chamberlain JS & Froehner SC (2008). Functional deficits in nNOSm-deficient skeletal muscle: myopathy in nNOS knockout mice. PLoS One 3, e3387.
42. Rutschman R, Lang R, Hesse M, Ihle JN,Wynn TA & Murray PJ (2001). Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol 166, 2173-2177.
43. Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD & Victor RG (2000). Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 97, 13818-13823.
44. Satriano J (2004). Arginine pathways and the inflammatory response: Interregulation of nitric oxide and polyamines: Review article. Amino Acids 23, 321-329.
45. Sciorati C, Buono R, Azzoni E, Casati S, Ciuffreda P, D'Angelo G, Cattaneo D, Brunelli S & Clementi E (2010). Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Br J Pharmacol 160, 1550-1560.
46. Scott GK, Mattie MD, Berger CE, Benz SC & Benz CC (2006). Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66, 1277-1281.
47. Sharma U, Atri S, Sharma MC, Sarkar C & Jagannathan NR (2003). Skeletal muscle metabolism in Duchenne muscular dystrophy (DMD): an in-vitro proton NMR spectroscopy study. Magn Reson Imaging 21, 145-153.
48. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, Xu X, Murphy E, Darley-Usmar VM & Gladwin MT (2007). Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res 100, 654-661.
49. Singel DJ & Stamler JS (2005). Chemical physiology of blood flow regulation by red blood cells: the role of nitric oxide and S-nitrosohemoglobin. Annu Rev Physiol 67, 99-145.
50. Stamler JS, Singel DJ & Loscalzo J (1992). Biochemistry of nitric oxide and its redox-activated forms. Science 258, 1898-1902.
51. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT & Kelly AM (1991). The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352, 536-539.
52. Straub V, Ratjen F, Amthor H, Voit T & Grasemann H (2002). Airway nitric oxide in Duchenne muscular dystrophy. J Pediatr 141, 132-134.
53. Tatsumi R, Anderson JE, Nevoret CJ, Halevy O & Allen RE (1998). HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev Biol 194, 114-128.
54. Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D & Boucher JL (1999). Effects of the new arginase inhibitor Nw-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide 3, 427-438.
55. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT & Victor RG (1998). Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 95, 15090-15095.
56. Thomas GD, Ye J, De Nardi C, Monopoli A, Ongini E & Victor RG (2012). Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. PLoS One 7, e49350.
57. Tidball JG, Lavergne E, Lau KS, SpencerMJ, Stull JT & Wehling M (1998). Mechanical loading regulates NOS expression and activity in developing and adult skeletal muscle. Am J Physiol Cell Physiol 275, C260-C266.
58. Uaesoontrachoon K, Quinn JL, Tatem KS, Van Der Meulen JH, Yu Q, Phadke A, Miller BK, Gordish-Dressman H, Ongini E, Miglietta D & Nagaraju K (2014). Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet 23, 3239-3249.
59. Uezumi A, Ito T, Morikawa D, Shimizu N, Yoneda T, Segawa M, Yamaguchi M, Ogawa R, Matev MM, Miyagoe-Suzuki Y, Takeda S, Tsujikawa K, Tsuchida K, Yamamoto H & Fukada S (2011). Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J Cell Sci 124, 3654-3664.
60. Vaghy PL, Fang J,Wu W & Vaghy LP (1998). Increased caveolin-3 levels in mdx mouse muscles. FEBS Lett 431, 125-127.
61. Villalta SA, Nguyen HX, Deng B, Gotoh T & Tidball JG (2009). Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 18, 482-496.
62. Voisin V, Sebrie C, Matecki S, Yu H, Gillet B, Ramonatxo M, Israel M & De la Porte S (2005). L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis 20, 123-130.
63. Wells KE, Torelli S, Lu Q, Brown SC, Partridge T,Muntoni F & Wells DJ (2003). Relocalization of neuronal nitric oxide synthase (nNOS) as a marker for complete restoration of the dystrophin associated protein complex in skeletal muscle. Neuromuscul Disord 13, 21-31.
64. Wineinger MA,Walsh SA & Abresch RT (1998). The effect of age and temperature on mdx muscle fatigue. Muscle Nerve 21,1075-1077.
65. Wehling M, Spencer MJ & Tidball JG (2001). A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 155, 123-131.
66. Wehling-Henricks M & Tidball JG (2011). Neuronal nitric oxide synthase-rescue of dystrophin/utrophin double knockout mice does not require nNOS localization to the cell membrane. PLoS One 6, e25071.
67. Wehling-Henricks M, Oltmann M, Rinaldi C, Myung KH & Tidball JG (2009). Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy. Hum Mol Genet 18, 3439-3451.
68. Wehling-Henricks M, Jordan MC, Gotoh T, Grody WW, Roos KP & Tidball JG (2010). Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy. PLoS One 5, e10763.
69. Yamada M, Sankoda Y, Tatsumi R, Mizunoya W, Ikeuchi Y, Sunagawa K & Allen RE (2008). Matrix metalloproteinase-2 mediates stretch-induced activation of skeletal muscle satellite cells in a nitric oxide-dependent manner. Int J Biochem Cell Biol 40, 2183-2191.